We first assessed the association of independent EZH2, H3K27me3, pAkt1, pS21EZH2 and EZH2/H3K27me3, pAkt1/pS21EZH2 combination with clinical characteristics of ovarian cancer patients such as age, histology, FIGO stage, tumor type and chemotherapy response. This evidence concerns the gene EZH2 and ovarian carcinoma.